Skip to main content
Clinical Trials/NCT04164355
NCT04164355
Completed
Not Applicable

Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days: a Single-centre Prospective-control

Federico II University1 site in 1 country40 target enrollmentJuly 4, 2020

Overview

Phase
Not Applicable
Intervention
Tadalafil 20 MG
Conditions
Erectile Dysfunction Following Radical Prostatectomy
Sponsor
Federico II University
Enrollment
40
Locations
1
Primary Endpoint
The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg using optical coherence tomography angiography.

Detailed Description

Tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection. This drug represents an treatment for erectile dysfunction in patients after radical prostatectomy. The optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. The study evaluates the changes in optical coherence tomography angiography parameters at baseline and after 1, 3, 6 months after the somministration of Tadalafil 20 mg orally.

Registry
clinicaltrials.gov
Start Date
July 4, 2020
End Date
April 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Gilda Cennamo

Principal Investigator

Federico II University

Eligibility Criteria

Inclusion Criteria

  • age older than 45 years
  • diagnosis of erectile dysfunction due to surgery of radical prostatectomy
  • treatment-naïve with Tadalafil for erectile dysfunction
  • absence of vitreoretinal and vascular retinal diseases
  • absence of diabetes

Exclusion Criteria

  • age younger than 45 years
  • diagnosis of erectile dysfunction due to other causes
  • previous treatments before Tadalafil for erectile dysfunction
  • presence of vitreoretinal and vascular retinal diseases
  • presence of diabetes.

Arms & Interventions

Patients undergoing Tadalafil

Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months

Intervention: Tadalafil 20 MG

Outcomes

Primary Outcomes

The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy

Time Frame: Six months

Changes in retinal and choriocapilary vessel density in 40 patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy, using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillary vessel density

Study Sites (1)

Loading locations...

Similar Trials